“I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the Continuous Blood Glucose Monitor (CBGM),” said Mr.
It was acquired in 2016 by the Malta-headquartered Corinthia Group, which lavished €150mn on the building’s restoration and renamed it Corinthia Brussels.